Published guidance, NICE advice and quality standards | Guidance

Showing 211 to 220 of 2013

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Bevacizumab gamma for treating wet age-related macular degeneration	TA1022	4 December 2024	4 December 2024
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer	TA214	23 February 2011	23 February 2011
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer	TA263	22 August 2012	22 August 2012
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer	TA285	22 May 2013	22 May 2013
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer	TA212	15 December 2010	15 December 2010
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer	TA284	22 May 2013	22 May 2013
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)	TA560	20 February 2019	20 February 2019
Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse	HTG539	4 March 2020	4 March 2020
Bimekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis	TA918	11 October 2023	11 October 2023
Bimekizumab for treating active psoriatic arthritis	TA916	4 October 2023	4 October 2023